BUY Ashok Leyland — Manas Jaiswal
byManas JaiswalHorizon: NA (inferred Swing (≤2wk))17 Aug 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
7 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·20 Aug · today
Ashok Leyland's Diversified Growth Story Intact, Says Nirmal Bang; Raises Target Price Post Q1 Results
NewsNdtv-Profit·17 Aug · 3d ago
Ashok Leyland shares in focus after Q1 results. What are Citi, Nomura analysts saying?
NewsEt-Markets·17 Aug · 3d ago
Ashok Leyland Q1 profit rises 2% as revenue jumps 10% to Rs 10,750 crore
NewsEt-Markets·14 Aug · 5d ago
Ashok Leyland Q1 Results: Net profit rises 2.59% YoY to ₹609 crore, revenue up 10.4%
NewsLivemint·14 Aug · 6d ago
Ashok Leyland just had a record June quarter. So why did the margin fall a full point?
NewsEt-Markets·18 Aug · yesterday
Buy, Sell Or Hold: Ashok Leyland, Physicswallah, Meesho, NALCO, Praj Industries — Ask Profit
NewsNdtv-Profit·18 Aug · 2d ago
Ashok Leyland’s demand is on the right track, but margins lag
NewsLivemint·17 Aug · 3d ago
Ashok Leyland Q1: Analysts See More Upside Despite Margin Pressure; Check New Target Prices
NewsNdtv-Profit·17 Aug · 3d ago
Q1 Results Highlights: Kwality Wall's Profit Rises 35%, NMDC Posts Subdued Growth
NewsNdtv-Profit·14 Aug · 6d ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Ashok Leyland
- BUY — Kotak Securities19 Oct 2026 · ~1 year · target ₹180 · Active
- BUY — Sumeet Bagadia, Choice Broking15 Oct 2026 · ~2 weeks · target ₹155 · SL hit
- SELL — Rajesh Satpute7 Oct 2026 · ~3 months · target ₹140 · Active
- BUY — Vishnu Kant Upadhyay, Master Capital Services6 Oct 2026 · ~2 weeks · target ₹175 · SL hit
- BUY — Gaurav Sharma, Globe Capital Market5 Oct 2026 · ~1 year · target ₹200 · Active
More from Manas Jaiswal
- BUY Ajanta Pharma23 Oct 2026 · Same day · target ₹3,425 · SL hit
- BUY Torrent Pharmaceuticals23 Oct 2026 · Same day · target ₹4,725 · SL hit
- BUY SAGILITY23 Oct 2026 · ~2 weeks · target ₹50 · SL hit
- BUY Zydus Lifesciences22 Oct 2026 · ~3 months · target ₹1,160 · SL hit
- BUY IPCA Laboratories22 Oct 2026 · ~2 weeks · target ₹2,000 · Active

